Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02

Arlene O Siefker-Radtke,Daniel C Cho,Adi Diab,Mario Sznol,Mehmet A Bilen,Arjun V Balar,Giovanni Grignani,Erika Puente,Lily Tang,David Chien,Ute Hoch,Arkopal Choudhury,Danni Yu,Sue L Currie,Mary A Tagliaferri,Jonathan Zalevsky,Michael E Hurwitz,Nizar M Tannir

European Urology（2022）

引用 2|浏览9

暂无评分

摘要

Bempegaldesleukin plus nivolumab was well tolerated and showed antitumor activity in this preliminary investigation of first-line treatment in patients with locally advanced or metastatic urothelial carcinoma in a phase 2 cohort from the open-label, multicohort phase 1/2 PIVOT-02 study.

查看译文

关键词

Interleukin-2,Nivolumab,Urothelial carcinoma,Transitional cell,Immunotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要